Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Late Relapse in Hodgkin Lymphoma (HL): A Retrospective Analysis of Patients Enrolled on Clinical Trials at the Istituto Nazionale Tumori of Milan (INT-MI)

Simonetta Viviani, MD, Alberto Mussetti, MD, Oreste Di Bartolo, MD, Antonello Cabras, MD, Pinuccia Valagussa, Statistician, Gianni Bonadonna, MD, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2015) 126 (23): 2697.

https://doi.org/10.1182/blood.V126.23.2697.2697

Published: 2015

Journal Articles

LONG-TERM Risk of Late Effects After Treatment for EARLY-STAGE HODGKIN'S Lymphoma (HL).

Simonetta Viviani, MD, Anna DI Russo, MD, Valeria Bonfante, MD, Pinuccia Valagussa, Gianni Bonadonna, MD, Alessandro M. Gianni, MD

Blood (2012) 120 (21): 2732.

https://doi.org/10.1182/blood.V120.21.2732.2732

Published: 2012

Journal Articles

High Response Rates to Bortezomib-Dexamethasone Followed by Donor Lymphocyte Infusions in Patients with Multiple Myeloma Relapsing After Allogeneic Stem Cell Transplantation: Results of a Multicentric Prospective Phase II Study

Vittorio Montefusco, MD, Francesco Spina, MD, Francesca Patriarca, MD, Massimo Offidani, MD, Benedetto Bruno, Lucia Farina, MD, PhD, Alessandra Sperotto, MD, Mara Morelli, MD, Anna Dodero, MD, Luisa Giaccone, Renato Fanin, Pinuccia Valagussa, Paolo Corradini, MD

Blood (2011) 118 (21): 828.

https://doi.org/10.1182/blood.V118.21.828.828

Published: 2011

Journal Articles

Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL)

Carmelo Carlo-Stella, MD, Anna Guidetti, MD, Simonetta Viviani, MD, Valeria Bonfante, MD, Pinuccia Valagussa, MD, Alfonso Marchianò, MD, Flavio Crippa, MD, Stefania Zambelli, MD, Cinzia Fasola, MD, Paolo Corradini, MD, Corrado Tarella, MD, Massimo Di Nicola, MD, Alessandro M. Gianni, MD

Blood (2008) 112 (11): 2586.

https://doi.org/10.1182/blood.V112.11.2586.2586

Published: 2008

Journal Articles

High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Promising Activity, Minimal Toxicity and Full Feasibility in an Outpatient Setting.

Liliana Devizzi, MD, Ettore Seregni, MD, Anna Guidetti, MD, Chiara Forni, MD, Angela Coliva, MD, Michele Magni, MD, Massimo Di Nicola, MD, Carmelo Carlo-Stella, MD, Paola Matteucci, MD, Antonella De Pascale, MD, Claudia Erminero, MD, Marco Maccauro, MD, Carlo Chiesa, PhD, Emilio Bombardieri, MD, Pinuccia Valagussa, Alessandro M. Gianni, MD

Blood (2006) 108 (11): 3047.

https://doi.org/10.1182/blood.V108.11.3047.3047

Published: 2006

Journal Articles

Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Stem Cell Transplantation (SCT) for Relapsed Lymphomas: Impact of Pre-Transplantation Factors on Long-Term Outcome.

Paolo Corradini, MD, Anna Dodero, MD, Marco Bregni, MD, Fabio Ciceri, MD, Attilio Olivieri, MD, Lucia Farina, MD, Pinuccia Valagussa, MD, Rosanna Scime’, MD, Anna Locasciulli, MD, Francesca Patriarca, MD, Alessandro Massimo Gianni, MD, Corrado Tarella, MD

Blood (2005) 106 (11): 1129.

https://doi.org/10.1182/blood.V106.11.1129.1129

Published: 2005

Journal Articles

Effect of Age and Previous Autologous Transplant on Treatment-Related Mortality and GVHD in 140 Patients Treated with Reduce-Intensity Conditioning and Allograft for Advanced Hematological Malignancies.

Paolo Corradini, M.D., Francesco Zallio, M.D., Jacopo Mariotti, M.D., Pinuccia Valagussa, M.D., Anna Dodero, M.D., Marco Bregni, M.D., Fabio Ciceri, M.D., Andrea Bacigalupo, M.D., Moira Lucesole, M.D., Francesca Patriarca, M.D., Andrea Rambaldi, M.D., Rosanna Scimè, M.D., Giuseppe Bandini, M.D., Alessandro M. Gianni, M.D., Corrado Tarella, M.D., Attilio Olivieri, M.D.

Blood (2004) 104 (11): 5138.

https://doi.org/10.1182/blood.V104.11.5138.5138

Published: 2004

Journal Articles

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma

Paolo Corradini, Michele Cavo, Henk Lokhorst, Giovanni Martinelli, Carolina Terragna, Ignazio Majolino, Pinuccia Valagussa, Mario Boccadoro, Diana Samson, Andrea Bacigalupo, Nigel Russell, Vittorio Montefusco, Claudia Voena, Gosta Gahrton, the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Blood (2003) 102 (5): 1927–1929.

https://doi.org/10.1182/blood-2003-01-0189

Published: 2003

NARROW

Late Relapse in Hodgkin Lymphoma (HL): A Retrospective Analysis of Patients Enrolled on Clinical Trials at the Istituto Nazionale Tumori of Milan (INT-MI)

LONG-TERM Risk of Late Effects After Treatment for EARLY-STAGE HODGKIN'S Lymphoma (HL).

High Response Rates to Bortezomib-Dexamethasone Followed by Donor Lymphocyte Infusions in Patients with Multiple Myeloma Relapsing After Allogeneic Stem Cell Transplantation: Results of a Multicentric Prospective Phase II Study

Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL)

High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Promising Activity, Minimal Toxicity and Full Feasibility in an Outpatient Setting.

Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Stem Cell Transplantation (SCT) for Relapsed Lymphomas: Impact of Pre-Transplantation Factors on Long-Term Outcome.

Effect of Age and Previous Autologous Transplant on Treatment-Related Mortality and GVHD in 140 Patients Treated with Reduce-Intensity Conditioning and Allograft for Advanced Hematological Malignancies.

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only